BiotechTube

Donepezil hydrochloride (Aricept)

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Down Syndrome

Conditions

Down Syndrome

Trial Timeline

Apr 4, 2008 → Dec 15, 2008

NCT ID
NCT00675025

About Donepezil hydrochloride (Aricept)

Donepezil hydrochloride (Aricept) is a phase 2 stage product being developed by Eisai for Down Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT00675025. Target conditions include Down Syndrome.

What happened to similar drugs?

1 of 3 similar drugs in Down Syndrome were approved

Approved (1) Terminated (2) Active (0)
✅Donanemab + PlaceboEli LillyApproved
❌Aricept (donepezil hydrochloride) + Aricept (donepezil hydrochloride) + PlaceboEisaiPhase 3
❌Aricept (Donepezil hydrochloride) + PlaceboEisaiPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT00675025Phase 2Terminated
NCT00711204ApprovedWithdrawn
NCT00165763ApprovedCompleted

Competing Products

13 competing products in Down Syndrome

See all competitors
ProductCompanyStageHype Score
Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)YuhanPhase 1
29
Aricept (donepezil hydrochloride) + Aricept (donepezil hydrochloride) + PlaceboEisaiPhase 3
32
Aricept (Donepezil hydrochloride) + PlaceboEisaiPhase 3
32
E2020-Donepezil hydrochloride + E2020-Donepezil hydrochloride + PlaceboEisaiPhase 2
35
Donepezil HCl + PlaceboEisaiPhase 2
35
Donanemab + PlaceboEli LillyApproved
50
Placebo + RG1662RochePhase 1
29
Placebo + RG1662 + RG1662RochePhase 2
35
Placebo + RO5186582RochePhase 2
27
RG1662 + placeboRochePhase 1
29
ELND005 + PlaceboElancoPhase 2
32
ACI-24 low dose + ACI-24 high dose + PlaceboAC ImmunePhase 1
19
ACI-24 + PlaceboAC ImmunePhase 2
17